CAPR (Capricor Therapeutics) Total Stockholders Equity: $278.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $18.91
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Total Stockholders Equity?

Capricor Therapeutics CAPR -4.40% 37 Total Stockholders Equity is $278.70 Mil as of Mar. 2026. GuruFocus rates CAPR with a GF Score™ of 37/100 and a GF Value™ of $4.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Capricor Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $278.70 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Capricor Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $4.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Capricor Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.05.

Capricor Therapeutics  (NAS:CAPR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Capricor Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(278.703-0)/57.665
=4.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Capricor Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.841 + 13.944) / 278.703
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Total Stockholders Equity Related Terms

Capricor Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Total Stockholders Equity Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.37 11.79 22.60 145.46 305.79

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 127.65 104.98 83.87 305.79 278.70
CAPR
37GF Score
Capricor Therapeutics Inc CAPR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $278.70 Mil mean?
Capricor Therapeutics (CAPR) has a Total Stockholders Equity of $278.70 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Total Stockholders Equity too high?
Capricor Therapeutics' current Total Stockholders Equity is $278.70 Mil. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Total Stockholders Equity compare to COAG and DMRA?
Capricor Therapeutics' Total Stockholders Equity of $278.70 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Capricor Therapeutics and its competitors. Capricor Therapeutics's current Total Stockholders Equity is $278.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $18.91 — trading 288.3% above its estimated fair value. The current Total Stockholders Equity is $278.70 Mil. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Total Stockholders Equity is $278.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $18.91 is trading 288.3% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • Total Stockholders Equity: $278.70 Mil
  • GF Value™: $4.87 vs. price of $18.91 (288.3% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.91
Price
$4.87
GF Value